Long-Term Follow-Up after Paediatric Kidney Transplantation and Influence Factors on Graft Survival: A Single-Centre Experience of 16 years by Friedersdorff, Frank et al.
Original Paper
Urol Int
Long-Term Follow-Up after Paediatric Kidney 
Transplantation and Influence Factors on Graft 
Survival: A Single-Centre Experience of 16 years
Frank Friedersdorff a    Therese-Marie Koch b    Beatriz Banuelos-Marco a    
Ricardo Gonzalez a    Tom Florian Fuller a    Stefanie von Mechow a    Dominik Müller b  
Anja Lingnau a    
a
 Department of Urology and Pediatric Urology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie 
Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; b Department of 
Pediatric Nephrology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-
Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
Received: November 20, 2017
Accepted after revision: January 15, 2018
Published online: March 7, 2018
Internationalis
Urologia
Priv.-Doz. Dr. med. Frank Friedersdorff
Department of Urology and Pediatric Urology
Charité – Universitätsmedizin Berlin
Charitéplatz 1, DE–10117 Berlin (Germany)
E-Mail frank.friedersdorff @ charite.de





Influence factors · Paediatric transplantation · Vascular 
complications
Abstract
Introduction: To evaluate graft- and patient survival after 
paediatric kidney transplantation and detecting influence 
factors, which affect the post-transplant time. Materials and 
Methods: We analysed long-term survival rates and compli-
cations after paediatric kidney transplantation and searched 
for predictive parameters for graft function. Results: In 132 
patients, 143 kidney transplantations were performed. Graft 
failure occurred in 25%. Chronic rejections were the leading 
cause of graft loss (42.9%). Graft survival rates were 92.2% 
after 1 year, 85.5% after 5 years, 71.1% after 10 years and 
62.1% after 15 years. The following parameters strongly in-
fluenced graft survival: number of transplants (p = 0.014), 
year of transplant (p < 0.0001 for 1997–2005), Epo-therapy 
post-transplant (p = 0.001), hypotension donor (p = 0.027), 
cold ischemia time (p = 0.023), anastomosis time >50 min 
(p = 0.008), delayed graft function (p = 0.003) and deceased 
donation (p = 0.039). The percentage of patients who died 
was 5.6%. Overall patient survival rates were 99.3% after 
1 year, 95.2% after 5 years, 94.2% after 10 years and 90.7% 
after 15 years. Various types of infections (42.9%) were the 
main causes of death. Conclusions: The main causes of 
death after kidney transplantations in paediatric recipients 
are malignancy and infections. To avoid vascular complica-
tions especially in young recipients (<9 years), the cold isch-
emia time should be as short as possible.
© 2018 S. Karger AG, Basel
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Introduction
Renal transplantation remains the treatment of choice 
for children with end-stage renal disease (ESRD). It con-
fers improved survival, growth and health-related quality 
of life compared to dialysis [1–3]. Due to new immuno-
suppressive medication, a decreased number of rejections 
and improvement of transplant- and patient outcome is 
seen. Since children receiving kidney transplants have a 
long expectancy of life, it is particularly important to 
maximize graft function and graft survival in this popula-
tion. Many times, children’s growth and development are 
already impaired in early stages of chronic renal disease. 
Forty percent of children with end-stage renal failure are 
situated below the 3rd percentile in growth curves [4]. 
Kidney transplantation can be considered the best thera-
py for ESRD. There are about 3,000 renal transplantations 
performed per year [5]. The mortality rate is 4–5 fold 
higher when dialysis is performed compared to organ 
transplantation [1].
Chronic transplant rejection is the most common 
reason for graft loss among children [4]. Further rea-
sons for chronic graft dysfunction are acute rejection, 
toxicity following the application of calcineurin inhibi-
tors, recurrence of the underlying renal disease process 
within the graft as well as cases of de-novo glomerulo-
nephritis [4].
In literature, the 5-year graft survival is 85% for living 
donation recipients and 78% for deceased donation recip-
ients [6]. The overall patient survival has been constantly 
improved within the past years. Smith et al. [7] reported 
3-year survival rates of 95% for living donation recipients 
and 93% for deceased donation recipients. Infections, neo-
plasia and cardiopulmonary diseases continue to be the 
most common reasons for recipients’ death [6]. 
Periods awaiting the transplantation, followed by ex-
tended duration of renal replacement therapy, are known 
to negatively influence the graft function and patient sur-
vival. Pre-emptively performed transplantations there-
fore lead to improved graft survival [8]. Approximately 
20% of transplantations in children are performed pre-
emptively [8]. 
Arterial hypertension significantly increases the risk 
for cardio-vascular morbidity and mortality. The preva-
lence of hypertension following kidney transplantation 
is about 50–80%, the aetiology being multifactorial [9]. 
The most common reasons for hypertension are pres-
ence of diseased native kidneys, pre-existing hyperten-
sion, renal artery stenosis as well as chronic allograft ne-
phropathy [10]. Left ventricular hypertrophy is a com-
mon result of end-organ damage in transplanted children 
[10]. Persisting growth retardation is associated with a 
worse medical outcome such as higher risk of re-hospi-
talization and has a major impact on the patients’ quality 
of life [11]. To achieve improved results concerning the 
patients’ growth, pre-emptive transplantation should be 
considered in addition to growth hormone treatment 
and application of new immunosuppressive drugs fol-
lowed by long-term immunosuppression without steroid 
intake [2]. Post-transplant growth spurts can be observed 
as physiological reaction in children of all ages within the 
first 6 months following transplantation [6]. Basic reason 
is steroid intake as well as the ending of alimentary re-
strictions. Obesity, however, increases the risk in cardio-
vascular disease and is considered an independent major 
risk factor for decrease in graft function [12]. The objec-
tive is therefore to initiate steroid-sparing protocols and 
as well as regular blood pressure assessments. Similarly, 
the nutritional intake should be optimized and patients 
should be encouraged to physical activities. With a prev-
alence of 33% post transplantation, urinary infections are 
considered an additional factor influencing the outcome 
of transplant recipients [13]. Basic risk factors could be 
identified such as urinary tract malformations, use of im-
munosuppressive drugs and urinary catheters [13]. Reg-
ular control and treatment for urinary infection are cru-
cial to minimize the risk of decrease in long-term graft 
function [13].
The aim of the present study was to evaluate the pa-
tient- and transplant outcomes over the time and to iden-
tify factors associated with poor outcomes. 
Materials and Methods
The entire analysis was performed with regard to the terms of 
the Charité Medical University of Berlin ensuring correct scien-
tific research work (“Good Scientific Practice,” version 06/10/14). 
The present study is a retrospective analysis and all patient data are 
anonymized.
Our database included paediatric renal transplant recipients 
up to 21 years of age from January 1997 to December 2013. Re-
cipients, who were transplanted at other centres, but treated in our 
hospital, were excluded from this study. The following preopera-
tive parameters were evaluated: patients and donors demographic 
data (age, body weight and height, donors condition (e.g., hypo-
tonic episodes), patients primary disease, type and duration of di-
alysis, previous operations, type of transplant, number of trans-
plant, infectious parameters such as EBV status and pre-trans-
plant transfusions.
We evaluated intraoperative parameters such as operating 
technique, intraoperative complications, ischemia time and post-

























   
   
   
   
   























sive therapy, rejection episodes, and further developmental pa-
rameters of the transplanted patient, such as re-hospitalization, 
medication, blood pressure, serum creatinine, compliance. For 
evaluating the data, we used information from hospital archive, 
Eurotransplant and SAP system. Furthermore, we used an online-
calculator (www.4c-study.org-calculators) for calculating height 
age, height SD score, body mass index, body mass index SD score 
for height age. 
Statistical Analyses
Statistical analyses were performed with SPSS 22 (IBM Corpo-
ration, Somers, NY, USA). Several non-parametric tests (Mann-
Whitney U test, Kruskal-Wallis test) were performed. Categorical 
variables were evaluated using the chi-square test. Predictors of 
graft survival were analysed by multivariable adjusted logistic re-
gression. A p value of less than 0.05 was considered significant.
Results
Patient Characteristics
In the present study, 143 paediatric transplants were 
included – 47% girls and 53% boys. The mean age at 
transplant was 11.5 years, with 18% of the children being 
younger than 5 years at the age of transplant. The most 
common diagnosis was “congenital anomalies of the kid-
ney and urinary tract” and other complex malformations 
associated with renal failure (34.1%) followed by glomer-
ulopathies (22.7%), haemolytic uremic syndrome 
(13.5%), tubulopathies (12.9%) and renal failure of other 
reasons. Living donation was performed in 24.5% of the 
cases.
Graft and Patient Survival
Overall mortality was 5.6%. Overall survival rate was 
99.3, 95.2, 94.2, and 90.7% after 1, 5, 10, and 15 years re-
spectively. Causes of death were post-transplant lympho-
proliferative disease (PTLD) 28%, myocarditis 28%, sep-
sis 14%, suicide 14% and traumatic events 4%.
Graft survival rates were 92.2, 85.5, 71.1, and 62.1% 
after 1, 5, 10, and 15 years respectively. 
Causes of graft failure were chronic rejection 43%, 
acute rejection 11.4%, vascular problems 14.3%, infec-
tions 5.7%, recurrence of primary disease 8.6% and graft 
failure of unknown origin 7.1%.
Within the period 1997–2005, graft failure was signif-
icantly higher compared with the period 2006–2013 (35.8 
vs. 2.1%, p < 0.001). Graft failure within the first year after 
transplant occurred frequently in the period 1997–2005, 
but it was not significant (p = 0.054). The graft survival 
was significantly different in favour of period 2006–2013 
(5-year graft survival 95 vs. 80%, p < 0.001). 
Influence Factors on Graft Survival
Several significant factors that depended on graft sur-
vival could be identified. The following factors are signif-
icant on graft survival: number of transplants (p = 0.014), 
year of transplant (p < 0.0001 for 1997–2005), Epo-thera-
py post-transplant (p = 0.001), hypotension donor (p = 
0.027), cold ischaemia time (p = 0.023), anastomosis time 
>50 min (p = 0.008), delayed graft function (p = 0.003) and 
deceased donation (p = 0.039). Figure 1 shows that the cu-
mulative graft survival depends on cold ischaemia time. 
The comparison of living and deceased donation regard-
ing graft and patient survival showed a statistically sig-
nificant difference (p = 0.039). Figure 2 shows a Kaplan-
Meier-Curve regarding cumulative graft survival.
The most common reason for graft failure was chron-
ic graft failure or graft dysfunction (42.9%). Other rea-
sons were vascular complications such as arterial and vein 
thrombosis or arterial stenosis (14.3%) or acute rejections 
(11.4%). Infectious reasons for graft loss were BK-virus 
and myocarditis. The mean age at the time of graft failure 
was 16.1 ± 6.7.
Surgical Complications
Intra- and postoperative complications occurred in 
55.2% of the cases. Within the complication group, a 
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to the non-complication group (p = 0.068). The most 
common complications were vascular events (29.3%). 
Renal artery stenosis occurred in 9.1% of all recipients. 
Renal artery thrombosis and renal vein thrombosis oc-
curred each at the rate of 1.4%. All recipients developing 
arterial or venous thrombosis experienced graft failure. 
Further complications were urological type (20.3%), 
lymphocele (19.5%), bleeding (12%), infections (7.5%) 
and abdominal complications (12.5%) such as ileus and 
subileus.
Discussion
Kidney transplantation plays an important role for 
children with ESRD. Through the transplant, the children 
have the chance to complete a healthy development of the 
kidneys. Furthermore, they have a significant survival ad-
vantage in comparison to dialysis [1, 14]. Both for the liv-
ing donation as well as for deceased donation, within the 
last decades, the graft survival could be improved [6, 15]. 
Smith et al. [6] showed an improved graft survival for the 
era 2003–2010 in comparison to 1987–2002. The present 
study showed equally results for deceased donation, part-
ly better graft survival rates for living donation in com-
parison to Smith et al. [6]. The share of living donations 
in comparison to other studies was the same or slightly 
higher [5, 16]. The overall short- and long-term graft sur-
vival after living donation was comparable to that report-
ed in the literature [16]. 
Vascular thromboses are one of the most common 
causes of transplant losses after chronic transplant re-
jection [7]. The present study confirmed this statement. 
Thromboses occurred with a frequency of 2.8%. All pa-
tients experienced a graft failure. There are various risk 
factors for the occurrence of transplant thromboses. 
The following factors can have an influence: deceased 
donation, cold ischaemia time >24 h, multiple trans-
plants, peritoneal dialysis, more than 5 blood transfu-
sions, donor age or recipients <6 years, thrombophilia 
and low blood pressure during transplantation [4, 7, 
17]. In order to avoid thromboses or renal artery steno-
sis, especially in cases of young recipients (age <9 years), 
the cold ischaemia time should be as short as possible. 
In our study, these complications occurred in cases of 
young recipients (age <9 years) and with a cold isch-
emia time >24 h. Mehrabi et al. [16] showed that severe 
hypotension of the donor is a risk factor for hypoxic 
damage of the renal graft. The present study could con-
firm this hypothesis. “Hypotension donor” was a sig-
nificant influencing factor on graft survival. It seems to 
affect the long-term graft survival and favoured a 
chronic transplant failure. The 1- and 5-year graft sur-
vival (95 and 89%) was slightly better compared with 
the literature [16]. The difference could be attributed to 
the fact that the comparative study dates back to 2004 
or a more recent period (1967–2003) [16]. If you look 
at only the living donor recipients in more recent lit-
erature, the graft survival rates are better (98.4% 1-year, 
94.2% 5-year) [6]. The graft survival of deceased dona-
tion was comparable with the literature [6]. The death-
censored graft survival after 15 years of follow-up was 
almost 60%. Studies showed that the 3-year graft sur-
vival of children by deceased donation has improved 
from 78.5% in the period from 1987–1995 to 92.8% in 
1996 and from 89.8 to 94.8% in living donation [7]. 
Within the investigated patient group, the 3-year pa-
tient survival was 96.8 vs. 97.9% for the 1997–2005 pe-
riod vs. 2005–2013. It was also comparable or slightly 
higher compared with literature [7]. The most common 
causes of death are infections, cardiopulmonary causes 
and malignant diseases, with nearly half of the patients 
dying with a functioning graft [6]. Infections, followed 
by the PTLD, were the most frequent causes of death 
according to the present study, so that this finding 



















































   
   
   
   
   























study, the proportion of children who died with a func-
tioning transplant was less than 50%. The statement in 
the literature that the PTLD represents a significant 
mortality factor among kidney transplanted children 
could be confirmed [7, 18]. The incidence of PTLD was 
comparable to that reported in other studies of 6.9 and 
4.4% [19, 20]. The median time after kidney transplan-
tation up to the onset of illness differs strongly in the 
literature with information between 7.2 months and 3.2 
years [19, 20]. In our study, we found a value of 1.7 
years. The increased incidence of PTLD among chil-
dren who received growth hormone therapy prior to 
kidney transplantation is controversially discussed in 
the literature [21]. Within the investigated patient 
group, no correlation could be detected, whereby the 
overall small number of cases of children affected by a 
PTLD must be considered. As an alternative to dialysis, 
AB0-incompatible kidney transplantation should also 
be considered as an effective treatment with acceptable 
incidence of developing malignant tumours or infec-
tions [22].
Conclusion
The main causes of death after kidney transplantations 
in paediatric recipients are malignancy and infections. 
Long-term problems are hypertension, cardiovascular 
diseases, development of growth and weight, urinary 
tract infections and malignancy. To avoid vascular com-
plications especially in young recipients (<9 years), the 
cold ischaemia time should be as short as possible.
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